Read articles related to the project

post image

Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo.

BACKGROUND AND AIMS: We have recently reported that monocytes can undergo functional and transcriptional reprogramming towards a long-term pro-inflammatory phenotype after brief in vitro exposure to atherogenic stimuli such as oxidized LDL. This process is termed ‘trained immunity’, and is mediated by epigenetic remodeling and a metabolic switch towards increased aerobic glycolysis. We hypothesize that

Read More →

post image

In-vitro experimental model of trained innate immunity in human primary monocytes.

BACKGROUND: Innate immune memory or ‘trained immunity’ has recently been described as an important property of cells of the innate immune system. Due to the increased interest in this important new field of immunological investigation we sought to determine the optimal conditions for an in-vitro experimental protocol of monocyte training using three of the most

Read More →

post image

Diabetes propels the risk for cardiovascular disease: sweet monocytes becoming aggressive?

Diabetes strongly predisposes to cardiovascular disease (CVD), the leading cause of mortality in these patients, as well as in the entire population. Hyperglycemia is an important cardiovascular risk factor as shown by the observation that even transient periods of hyperglycemia, despite return to normoglycemia during follow-up, increase the risk for CVD, a phenomenon termed ‘hyperglycemic

Read More →

post image

Linked BLUEPRINT epigenetics project delivers beyond expectation

BLUEPRINT was officially launched on 1 October 2011. With the principal funding of €30 million by the European Union the project has been the European cornerstone of the international research cooperation effort International Human Epigenome Consortium, bringing together organisations and researchers from across the globe. Involving 42 leading European universities, research institutes, small and medium-sized

Read More →

Publication in Circulation Aug 05-2016: Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans.

In this translational work, we provide evidence in support of the concept that pro inflammatory oxidized phospholipids are major contributors to the atherogenicity of Lipoprotein(a) [Lp(a)] by showing that (1) subjects with elevated Lp(a) have increased arterial inflammation in vivo, (2) monocytes isolated from subjects with elevated Lp(a) remain in a long-lasting activated state ex

Read More →

post image

Prestigious Spinoza Prize won by Prof. dr. Mihai Netea (Radboud University Medical Center)

Prof. dr. Mihai Netea, full partner in REPROGRAM, was awarded the Spinoza Prize 2016, the highest award in Dutch science. Every year, the Netherlands Organisation for Scientific Research (NWO) awards the Spinoza Prize. The winners were announced by NWO chairman Jos Engelen on Friday 10 June. The NWO Spinoza Prize is both an award and

Read More →

post image

Scientific publication in European Heart Journal

Prof. Matthias Nahrendorf (Harvard Medical School), a key-partner within the REPROGRAM in collaboration with Prof. Filip K. Swirski published a scientific article in the European Heart Journal (Impact factor 15.2) on a topic highly related to REPROGRAM. You will find his article here .

Read More →

post image

Kick-off meeting REPROGRAM

On February 1 2016, the project members of REPROGRAM gathered at Schiphol Amsterdam airport for the official Kick-off meeting. After an inspiring introduction by the Prof. Dr. Erik Stroes (Project Coordinator) a crash course in Epigenetic Reprogramming was provided by Siroon Bekkering (Postdoctoral Researcher, AMC). With this encouraging launch in our minds, presentations per work

Read More →

1 2 3

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N°667837.